Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it...